Koichi Oki

Koichi Oki

Auto-generated profile, based on publicly available information

Koichi Oki

Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
KOKoichi Oki
Koichi Oki
MKMasahiro Katsumata
Masahiro Katsumata
YIYoshikane Izawa
Yoshikane Izawa
STShinichi Takahashi
Shinichi Takahashi
NSNorihiro Suzuki
Norihiro Suzuki
KHKiyohiro Houkin
Kiyohiro Houkin

9 September 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
KOKensuke Okada
Kensuke Okada
MSMorinobu Seki
Morinobu Seki
HYHiroshi Yaguchi
Hiroshi Yaguchi
KSKenichi Sakuta
Kenichi Sakuta
TMTaiji Mukai
Taiji Mukai
SSShigeaki Suzuki
Shigeaki Suzuki

3 July 2023 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
PDF file
KOKoichi Oki
Koichi Oki
MNMakoto Nakajima
Makoto Nakajima
TKTetsuo Koyama
Tetsuo Koyama
NONaoki Oyama
Naoki Oyama
MKMasatoshi Koga
Masatoshi Koga
PRProject Team for the Equalization and Standardization in Acute Stroke Rehabilitation
Project Team for the Equalization and Standardization in Acute Stroke Rehabilitation
Introduction: Many guidelines now recommend early rehabilitation for acute stroke patients. However, evidence remains lacking regarding the specific timings for initiation of various rehabilitation steps and management when complications are encountered in acute stroke rehabilitation. This survey aimed to investigate actual clinical situations in acute stroke rehabilitation in Japan and to improve the medical systems for rehabilitation and plan further studies. Methods: This nationwide, cross-sectional, web-based questionnaire survey was administered between February 7, 2022, and April 21, 2022, targeting all primary stroke centers (PSCs) in Japan. Among several components of the survey, this paper focused on the timing of the initiation of three rehabilitation steps (passive bed exercise; head elevation; and out-of-bed mobilization), along with the management of rehabilitation (continued or suspended) in the event of complications during acute stroke rehabilitation. We also investigated the influence of facility features on these contents. Results: Responses were obtained from 639 of the 959 PSCs surveyed (response rate: 66.6%). In cases of ischemic stroke and intracerebral hemorrhage, most PSCs initiated passive bed exercise on day 1, head elevation on day 1, and out-of-bed mobilization on day 2 (with day of admission defined as day 1). In cases with subarachnoid hemorrhage, rehabilitation steps were delayed compared to other stroke subtypes or showed wide variation depending on the facility. Passive bed exercise was accelerated by the presence of protocols for rehabilitation and weekend rehabilitation. Out-of-bed mobilization was accelerated by the presence of a stroke care unit. Facilities with board-certified rehabilitation doctors were cautious regarding the initiation of head elevation. Most PSCs suspended rehabilitation training in the event of symptomatic systemic/neurological complications. Conclusion: Our survey revealed the actual situation of acute stroke rehabilitation in Japan and indicated that some facility features appear to influence early increases in physical activity levels and early mobilization. Our survey provides fundamental data to improve the medical systems for acute stroke rehabilitation in the future.

18 September 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
SUShinichiro Uchiyama
Shinichiro Uchiyama
KSKatsue Suzuki-Inoue
Katsue Suzuki-Inoue
Hideo WadaHideo Wada
Hideo Wada
YOYasushi Okada
Yasushi Okada
THTeruyuki Hirano
Teruyuki Hirano
MKMasahide Kawamura
Masahide Kawamura
Introduction: Soluble C-type lectin-like receptor 2 (sCLEC-2) is a new biomarker for platelet activation, which can be easily measured by usual blood collection. We conducted the CLECSTRO, a prospective, observational cohort study, to evaluate the clinical implications of sCLEC-2 in patients with acute ischaemic stroke (AIS) and transient ischaemic attack (TIA). Methods and analysis: The participants are patients with AIS/TIA and control patients required for differentiation from AIS/TIA. The target population is 600, including the patients and controls, who would be recruited from eight stroke centres across Japan. The inclusion criteria are AIS within 24 hours of onset and a modified Rankin Scale (mRS) score of 0–2, TIA within 7 days of onset, and contemporary patients required for differentiation from AIS/TIA. Plasma sCLEC-2 will be measured by high-sensitive chemiluminescent enzyme immunoassay using residual blood samples from routine laboratory examinations at the first visit in all patients and 7 days later or at discharge in patients with AIS/TIA. The outcomes include plasma levels of sCLEC-2 in patients with AIS/TIA and controls, sCLEC-2/D-dimer ratio in non-cardioembolic and cardioembolic AIS/TIA, correlation of sCLEC-2 with recurrence or worsening of stroke, severity of stroke, infarct size, ABCD 2 score in TIA and outcome (mRS) at 7 days and 3 months. Ethics and dissemination: This study was approved by the Ethical Committee of the University of Yamanashi as the central ethical committee in agreement with the ethical committees of all collaborative stroke centres. Informed consent will be obtained by an opt-out form from the patients at each stroke centre according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Japanese Ministry of Health, Labour and Welfare. Trial registration numbers: NCT05579405 , UMIN000048954

1 December 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
TITakashi Iizuka
Takashi Iizuka
KOKoichi Oki
Koichi Oki
KHKentaro Hayashida
Kentaro Hayashida
KMKazushi Minami
Kazushi Minami
YIYoshikane Izawa
Yoshikane Izawa
JNJin Nakahara
Jin Nakahara

1 January 2022 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SSSho Shimohama
Sho Shimohama
KOKoichi Oki
Koichi Oki
HNHidefumi Narita
Hidefumi Narita
KMKyoko Mashima
Kyoko Mashima
SYSatoshi Yamada
Satoshi Yamada
HHHaruhiko Hoshino
Haruhiko Hoshino
We herein report a 70-year-old man with recurrent multiple cerebral infarctions under warfarin therapy who was finally diagnosed with Trousseau's syndrome resulting from advanced bladder cancer. A histological examination of the mesenteric lymph nodes revealed metastasis of micropapillary urothelial cancer with positive mucin markers CA125 and MUC1. Blood examinations also indicated elevated tumor markers, such as CA19-9 and CA125. To our knowledge, this is the first report of Trousseau's syndrome in a patient with bladder micropapillary urothelial cancer in which mucin involvement was clearly proven by histological and serological examinations.